导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.92% | 2449/4773 |
| 近一周 | -1.96% | 966/5462 |
| 近一月 | -3.92% | 2078/5421 |
| 近一季 | -6.35% | 2060/5209 |
| 近半年 | -2.62% | 1967/4920 |
| 近一年 | 1.08% | 2410/4366 |
| 近两年 | 45.73% | 1615/2954 |
| 近三年 | 27.38% | 1165/2253 |
| 成立以来 | 104.21% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.28% 3110/4961 |
11.86% 2281/5312 |
- - |
- - |
| 2025 | 19.28% 2233/4813 |
-0.96% 2491/3635 |
1.87% 2070/4076 |
18.09% 2350/4524 |
0.11% 2207/4813 |
| 2024 | 14.27% 1062/3463 |
2.16% 810/2808 |
-1.66% 1090/3014 |
15.90% 1595/3129 |
-1.87% 1871/3463 |
| 2023 | -10.12% 1269/2656 |
2.77% 1303/2280 |
-4.54% 1195/2385 |
-3.28% 887/2515 |
-5.27% 1309/2655 |
| 2022 | -16.68% 503/2207 |
-13.55% 778/1919 |
7.29% 497/2016 |
-11.72% 568/2113 |
1.74% 1162/2208 |
| 2021 | 5.69% 539/1822 |
-2.31% 615/1255 |
8.65% 609/1330 |
-2.88% 601/1466 |
2.52% 570/1822 |
| 2020 | 40.32% 311/1250 |
-6.45% 486/1028 |
16.77% 415/1067 |
13.52% 316/1164 |
13.15% 387/1184 |
| 2019 | 38.67% 303/1092 |
25.45% 466/739 |
-0.24% 235/788 |
2.58% 295/850 |
8.02% 364/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华泰MSCI中国A股联接A VS. 长安沪深300非周期A(740101) |